Investors Target Embecta Corp. Following Earnings Collapse

The legal challenge follows a disastrous second-quarter earnings report that shattered investor confidence. Throughout the class period, Embecta management repeatedly characterized its core pen needle portfolio as resilient and durable, even as the company reiterated its adjusted EPS guidance of $2.80 to $3.00 on February 5, 2026. The lawsuit claims these assurances were either knowingly false or reckless, ignoring mounting market weaknesses that eventually forced a major pivot.

On May 5, 2026, the company’s narrative collapsed. Embecta reported adjusted EPS of $0.27, representing a 61% decline, and slashed its full-year EPS guidance to a range of $1.55 to $1.75. The company further signaled its financial distress by cutting its dividend by 93% to a symbolic $0.01 per share. The subsequent stock selloff prompted Hagens Berman to launch an investigation into whether executives intentionally concealed revenue headwinds. Reed Kathrein, a partner at the firm, stated the investigation specifically targets the timeline of management's awareness regarding these risks and their transparency with the public. Investors who suffered losses have until August 17, 2026, to serve as lead plaintiffs.